|
|
|
Highest Medicl Unmet Needs
|
Acelerating
Lupus Discovery
|
|
From Target Validation to Preclinical Effiacy
|
|
[Integrated MRL/FASlpr & NZW/B F1 Platforms for Translational Success]
|
|
|
Optimized Efficacy
Evaluation Platform
|
|
Reliable Data for Your IND Submission
|
|
Preclina has launched the “PreVIVO™” service, designed to
maximize cost-efficiency and shorten development timelines.
|
Accelerated
Turnaround Time
|
|
Accelerated
Turnaround Time
|
|
Accelerated
Turnaround Time
|
|
Accelerated
Turnaround Time
|
|
|
|
|
|
Bridging the Transational Gap
in Lupus Drug Discovery
|
|
From Standard of Care to Novel Therapeutics
|
PBMC-Humanized Mouse Model
[PreHu™-P Model]
|
|
Heterogeneity & Complexity:
High patient variability and multi-organ involvement (skin, kidney, CNS) complicate clinical trial designs.
|
|
Limitations of Current SOC:
Despite advances, long-term remission remains elusive, demanding novel MOA-based therapies.
|
|
Critical Quality Gap in Preclinical Data:
Inadequate scientific rigor in reproducibility and predictive clinical translation undermines the value of large animal critical data.
|
|
|
|
Strategic Study Design for IND Success
|
Translational Intelligence & Risk Mitigation
|
|
 Target-Specific Model Selection:Guidance on choosing MRL/Faslpr vs NZW/B F1 based on your MOA.
Customized Endpoints: Beyond survival—incorporating diverse biomarkers & pathology scoring.
|
Bridging Data Gaps:Correlating preclinical efficacy with potential clinical outcomes.
Go/No-Go Decision Support:Objective data analysis to de-risk your pipeline before IND.
|
|
|
|
|
|
|
Strategic Lupus Model Portfolio
|
|
Aligning Drug MOA with Disease Pathogenesis
|
|
Optimized Model Selection
We offer distinct murine models optimized for your candidate’s specific immunological target and study timeline.
|
|
|
Multidimensional Profiling
|
|
From Clinical Phenotypes to Molecular Mechanisms
|
|
Holistic Disease Assessment
Simultaneous evaluation of phenotype & mechanism. Reducing pipeline lead time through integrated analysis
| Standardized Readouts |
|
Clinical: Body weight, Skin score, Proteinuria
Immunological: Autoantibody (anti-dsDNA), FACS analysis
Pathological: Glomerulonephritis & Interstitial scoring
|
|
|
|
Precision Renal Pathology &
Automated Digital Quantification
|
Precision Scoring of Glomerular &
Tubulointerstitial Lesions
Quantitative Morphometry for IND-Ready Data: Assessing
glomerular cellularity, crescent formation, and immune complex deposition.
Ensuring Data Integrity through Objective Evaluation and
Rigorous Pathological Review.
|
|
|
|
Mechanistic Insight &
Advanced MOA Profiling
|
|
|
|
Mechanistic
Insight (MOA):
Elucidating Target-Specific immune modulation pathways
|
|
|
Translational
Biomarkers
Bridging murine efficacy to human clinical endpoints
|
|
|
Regulatory Data Package
Supporting IND filing and providing data readiness for LO
|
|
|
|
Comprehensive Biomarker Profiling
Serological Markers:Anti-dsDNA (IgG/IgM), C3/C4 complement levels, ANA titers.
Cytokine Profiling:Serum/Tissue cytokine analysis(IL-6, TNF-α , IFN-γ, etc.) via Multiplex analysis.
Advanced Immunophenotyping (Typical)
T Cell Subsets: Th1, Th2, Th17, and Tregs balance.
B Cell Activation: Plasma cells, Memory B cells, and GC formation.
Intracellular Cytokine Staining with functionality assays.
|
|
|
Strategic Partnership for
Accelerated Lupus Drug Discovery
|
|
Accelerating Discovery with an Integrated PreVIVO™ Platform
Minimizing Lead Optimization Time & Maximizing Success Rates.
|
|
|
|
|
Follow us
|
|
© 2024 Precilina. All rights reserved.
Our mailing address is: 719 & 1302, Teratower B, 167, Songpa-daero,
Songpa-gu, Seoul 05855, Korea
|
|
